The comparative analysis of AML patients of <60 years, 60–74 years, and >75 years clearly showed that with aging there is an increase in the frequency of TET2, ASXL1, RUNX1, IDH2, and TP53 mutation frequency [51]. This evidence concerns the gene IDH2 and acute myeloid leukemia.